| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,855 |
8,729 |
$858K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,813 |
5,095 |
$699K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
5,973 |
5,490 |
$376K |
| 90670 |
|
1,587 |
1,572 |
$307K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,728 |
2,695 |
$298K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,545 |
2,523 |
$258K |
| 90461 |
|
3,468 |
3,444 |
$237K |
| 90698 |
|
2,033 |
2,022 |
$202K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,805 |
1,790 |
$199K |
| 90680 |
|
1,501 |
1,495 |
$129K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,275 |
2,155 |
$109K |
| 90716 |
|
759 |
751 |
$107K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,360 |
3,320 |
$101K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,015 |
1,906 |
$96K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
363 |
349 |
$81K |
| 90686 |
|
3,920 |
3,900 |
$76K |
| 90671 |
|
302 |
302 |
$71K |
| 90677 |
|
232 |
230 |
$67K |
| 90707 |
|
776 |
767 |
$62K |
| 99177 |
|
3,024 |
2,997 |
$48K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
362 |
360 |
$44K |
| 99051 |
|
1,589 |
1,520 |
$41K |
| 90633 |
|
1,010 |
997 |
$33K |
| 87634 |
|
653 |
620 |
$29K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,285 |
2,173 |
$25K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,378 |
2,345 |
$21K |
| 90744 |
|
808 |
806 |
$20K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
812 |
774 |
$18K |
| 87070 |
|
1,903 |
1,835 |
$16K |
| 90697 |
|
95 |
95 |
$14K |
| 90381 |
|
26 |
26 |
$13K |
| 90619 |
|
76 |
76 |
$11K |
| 81001 |
|
3,591 |
3,460 |
$11K |
| 85027 |
|
2,354 |
2,266 |
$11K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
334 |
271 |
$10K |
| 90651 |
|
38 |
38 |
$9K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
228 |
197 |
$9K |
| 99050 |
|
383 |
348 |
$9K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
784 |
359 |
$8K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,040 |
964 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
149 |
141 |
$7K |
| 90656 |
|
275 |
275 |
$6K |
| J0558 |
Injection, penicillin g benzathine and penicillin g procaine, 100,000 units |
29 |
28 |
$5K |
| 90685 |
|
194 |
187 |
$4K |
| 87280 |
|
287 |
269 |
$3K |
| 0072A |
|
75 |
75 |
$3K |
| 82465 |
|
749 |
741 |
$3K |
| 90756 |
|
86 |
85 |
$2K |
| 90696 |
|
39 |
39 |
$2K |
| 90688 |
|
87 |
87 |
$2K |
| 0071A |
|
74 |
74 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
209 |
176 |
$2K |
| 87088 |
|
194 |
176 |
$2K |
| 96127 |
|
140 |
139 |
$1K |
| 0002A |
|
44 |
44 |
$1K |
| 36416 |
|
4,019 |
3,481 |
$1K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
51 |
51 |
$1K |
| 0001A |
|
47 |
46 |
$1K |
| 90715 |
|
25 |
25 |
$937.36 |
| 87581 |
|
36 |
36 |
$759.33 |
| 80061 |
Lipid panel |
60 |
60 |
$684.40 |
| 96381 |
|
27 |
27 |
$667.83 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
21 |
21 |
$651.42 |
| 0083A |
|
12 |
12 |
$622.00 |
| 0082A |
|
12 |
12 |
$620.00 |
| 0004A |
|
18 |
17 |
$618.95 |
| 87276 |
|
39 |
37 |
$416.44 |
| 87275 |
|
39 |
37 |
$416.44 |
| 97802 |
|
4,242 |
2,568 |
$360.00 |
| 87807 |
|
33 |
32 |
$333.60 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
13 |
12 |
$304.98 |
| 36415 |
Collection of venous blood by venipuncture |
40 |
39 |
$204.57 |
| 90687 |
|
14 |
14 |
$112.80 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
43 |
26 |
$73.88 |
| 99072 |
|
711 |
656 |
$20.00 |
| 94760 |
|
39 |
36 |
$2.70 |
| S9451 |
Exercise classes, non-physician provider, per session |
239 |
237 |
$0.00 |
| 91307 |
|
18 |
17 |
$0.00 |
| 91308 |
|
37 |
32 |
$0.00 |